IL-17 mediates resistance to anti-VEGF therapy
- PMID: 24013745
- DOI: 10.1038/nm.3333
IL-17 mediates resistance to anti-VEGF therapy
Abstract
Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy.
Comment on
-
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4. Nat Med. 2013. PMID: 23913124
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
